The UK and US have reached a significant trade agreement that will guarantee zero levies on UK medicine shipments being sold in the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to increase funding on pharmaceuticals through the National Health Service (NHS). This move ensures that duties on these crucial exports will remain at nothing for a period of the next three years.
This agreement follows previous threats to significantly raise import taxes on patented drug products, with figures floated up to double the cost.
"This agreement between the United Kingdom strengthens the global environment for new treatments and brings long-overdue equity to U.S.–U.K. drug exports," an announcement said.
Economic Significance
Drugs constitute one of the UK's largest goods shipped to the US, which is clearly the primary destination for major UK drugmakers.
Statistics show that in the year prior to the third quarter, the UK sold drugs totaling billions to the US. This amount represented a significant portion of British export trade in that span.
"This agreement protects employment, increases funding and facilitates the UK to become a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Specific British Pledges
The pact includes several notable pledges from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to raise total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The percentage manufacturers must return to the NHS to prevent overspending will be limited at 15%. In the past, rebates topped 20%.
Industry Background
The pact takes place against a long-running row between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
This friction were intensified by arguments that US consumers were charged several times more for the same drugs than consumers in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been paused or scrapped, while major investments have been pledged toward American operations.
One official stated that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
